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Abstract 
 
2-[18F]fluoro-2-deoxy-D-glucose (18FDG) is a tumor diagnostic radiotracer of great 
importance in both diagnosing primary and metastatic tumors and in monitoring the efficacy 
of the treatment. P-glycoprotein (Pgp) is an active transporter that is often expressed in 
various malignancies either intrinsically or appears later upon disease progression or in 
response to chemotherapy. Several authors reported that the accumulation of 18FDG in P-
glycoprotein (Pgp) expressing cancer cells (Pgp+) and tumors is different from the 
accumulation of the tracer in Pgp nonexpressing (Pgp−) ones, therefore we investigated 
whether 18FDG is a substrate or modulator of Pgp pump. 
Rhodamine 123 (R123) accumulation experiments and ATPase assay were used to 
detect whether 18FDG is substrate for Pgp. The accumulation and efflux kinetics of 18FDG 
were examined in two different human gynecologic (A2780/A2780AD and KB-3-1/KB-V1) 
and a mouse fibroblast (3T3 and 3T3MDR1) Pgp+ and Pgp− cancer cell line pairs both in cell 
suspension and monolayer cultures.  
We found that 18FDG and its derivatives did not affect either the R123 accumulation in 
Pgp+ cells or the basal and the substrate stimulated ATPase activity of Pgp supporting that 
they are not substrates or modulators of the pump. Measuring the accumulation and efflux 
kinetics of 18FDG in different Pgp+ and Pgp- cell line pairs, we have found that the Pgp+ cells 
exhibited significantly higher (p≤0.01) 18FDG accumulation and slightly faster 18FDG efflux 
kinetics compared to their Pgp- counterparts.  The above data support the idea that expression 
of Pgp may increase the energy demand of cells resulting in higher 18FDG accumulation and 
faster efflux.  
We concluded that 18FDG and its metabolites are not substrates of Pgp. 
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Abbreviations 
 
CSA  cyclosporin A 
18FDG  2-[18F]fluoro-2-deoxy-D-glucose 
FDG  2-[19F]fluoro-2-deoxy-D-glucose 
18FDG-6-P 2-[18F]fluoro-2-deoxy-D-glucose-6-phosphate 
FDG-6-P 2-[19F]fluoro-2-deoxy-D-glucose-6-phosphate 
GLUT  glucose transporter 
HK-II  hexokinase enzyme type II 
MDR  multidrug resistance 
PET  positron emission tomography 
Pgp  P-glycoprotein 
Pgp+  P-glycoprotein positive 
Pgp−  P-glycoprotein negative 
R123  Rhodamine 123 
 
 
 
 
 
 
 
 
 
 
  
 4
Chemical compounds studied in this article: 
2-Chloro-2-deoxy-D-glucose  PubChem CID: 151933 
Cyclosporin A   PubChem CID: 5284373 
2-deoxy-D-glucose   PubChem CID: 108223 
Doxorubicin    PubChem CID: 31703 
2-Fluoro-2-deoxy-D-glucose  PubChem CID: 170049 
[18F]Fluoro-2-deoxy-2-D-glucose PubChem CID: 3232583 
Rhodamine 123   PubChem CID: 65217 
Verapamil hydrochloride  PubChem CID: 62969 
Vinblastine    PubChem CID: 241903 
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1. Introduction 
In routine clinical trials, the introduction of 18FDG-PET/CT has lead to a significant 
improvement in diagnostic accuracy and exerted a considerable impact on patient 
management including detecting the primary and metastatic tumors, staging, restaging, 
therapy monitoring, optimization of treatment, follow up of the efficacy of the treatment and 
prognosis prediction of different malignant tumors (Vallabhajosula, 2007; Kitajima et al., 
2011). 18FDG is the most commonly used PET tumor diagnostic radiotracer that allows 
visualization of the changes in the glucose metabolic rate in tumors (Wahl, 1996; Weber, 
2005; Kitajima et al., 2011). 18FDG is transported into the cells by glucose transporters where 
it becomes phosphorylated by hexokinases to 2-[18F]fluoro-2-deoxy-D-glucose-6-phosphate 
(18FDG-6-P). 18FDG-6-P is entrapped in the cells immediately after phosphorylation. Glucose 
6-phosphatase dephosphorylates 18FDG-6-P to 18FDG, which allows slight efflux of 18FDG 
from the cells (Wahl, 1996; Southworth et al., 2003; Ong et al., 2008). 
Pgp mediated multidrug resistance (MDR) seems to be the most widely observed 
mechanism in clinical cases of chemotherapy resistance and is known to protect the different 
tissues from a variety of exogenous and endogenous substances (Goda et al., 2009; Breier et 
al., 2013). Generally, Pgp substrates are organic amphipathic molecules ranging in size from 
about 200 to almost 1900 Daltons. The first identified Pgp substrates were chemotherapeutic 
drugs used in cancer chemotherapy, such a taxanes, anthracyclines, vinca alkaloids. However, 
many commonly prescribed drugs from various chemical and pharmacological classes are 
now known to be Pgp substrates (Endres et al., 2006; Eyal et al., 2009). Consequently, the 
detection of Pgp expression as well as overcoming the Pgp mediated active efflux of 
chemotherapeutic drugs from the tumor cells are important prerequisites of successful 
chemotherapy.  
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Positron emission tomography (PET) and single-photon emission tomography 
(SPECT) seems to be the most useful methods to study multidrug resistance in tumour tissues 
in vivo (Mairinger et al., 2011). Several authors reported different 18FDG accumulation in 
multidrug resistant and sensitive cancer cells and/or tumors.  A number of them accounted 
decreased accumulation of 18FDG in different cancer cells which express high level of Pgp 
(Lorke et al., 2001; Higashi et al., 2004; Yamada et al., 2005; Seo et al., 2009; Smith, 2010; 
Yu et al., 2012). It was also reported that certain Pgp modulators e.g. verapamil or 
cepharanthine restored the uptake of 18FDG and this finding was interpreted to suggest that 
18FDG might be a substrate of Pgp (Seo et al., 2009). In contrary with the above observations, 
we measured higher 18FDG uptake in the Pgp+ cells compared to their Pgp- counterpart in case 
of the A2780/A2780AD and KB-3-1/KB-V-1 human gynecologic cancer cell pairs (Márián et 
al., 2003; Krasznai et al., 2006).  
Since 18FDG is one of the most commonly used tumordiagnostic tracer, in the present 
work we aimed to determine whether 18FDG is a substrate or inhibitor of Pgp. The 
accumulation and the efflux kinetics of 18FDG were measured in two different human 
gynecologic cell pairs (A2780/A2780AD and KB-3-1/KB-V-1) and in a mouse fibroblast 
(NIH 3T3 and NIH 3T3 MDR1) cell line pair.  In order to define whether a quantitative 
relationship exists between the expression levels of GLUT-1, GLUT-3, hexokinase-II (HK-II) 
and 18FDG uptake, the expression levels of the above proteins were also measured parallel to 
the 18FDG accumulation measurements using flow cytometry.  
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2. Materials and methods 
2.1. Cell Lines 
Drug-resistant (Pgp+) cell lines and their non-resistant  (Pgp-) counterparts were used 
in the experiments. The human cervix carcinoma cell line pair (KB-V1 (Pgp+) and KB-3-1 
(Pgp-); Akiyama et al., 1985; Shen et al., 1986), the human ovarian carcinoma cell lines 
(A2780AD (Pgp+) and A2780 (Pgp-); Louie et al., 1986)  and the NIH 3T3 mouse fibroblast 
cell line and its human mdr1-transfected counterpart (NIH 3T3 MDR1 G185; Brugemann et 
al., 1992) were grown as monolayer cultures at 37°C in a 95% humidified air, 5% CO2 
atmosphere. The cell lines were maintained in 75 cm2 flasks in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 4.5 g/l glucose and supplemented with 10% heat-inactivated 
fetal bovine serum (FBS), 2 mM L-glutamine and 25 µM/ml gentamycin. The KB-V1 cells 
were cultured in the presence of 180 nM vinblastine. The A2780AD and NIH 3T3 MDR1 
cells were cultured in the presence of 2 µM and 670 nM doxorubicin, respectively. The cells 
were trypsinized two-three days before the experiments and maintained without drugs until 
harvesting them at the upper 2/3 part of the log phase. The cell viability was always higher 
than 90%, as assessed by the trypan blue exclusion test. 
2.2. Membrane preparation 
The NIH 3T3 MDR1 G185 human mdr1-transfected mouse fibroblast cells obtained 
from Michael Gottesman’s laboratory (National Institutes of Health, Bethesda, MD) were 
harvested by scraping them into phosphate buffered saline (PBS, pH=7.4) and washed twice. 
Membrane preparation was carried out according to (Sarkadi et al., 1992) with minor 
modifications. The cells were lysed and homogenized using glass-Teflon tissue homogenizer 
in TMEP (50 mM Tris, pH 7.0, 50 mM mannitol, 2 mM EGTA, 0.5 mM 
phenylmethylsulfonyl fluoride, and protease inhibitor cocktail (Sigma P2714)), then the 
undisrupted cells and nuclear debris were removed by centrifugation at 500 × g for 10 min. 
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The supernatant was centrifuged for 60 min at 28,000 × g and the pellet containing the 
membranes was resuspended in TMEP. All procedures were carried out at 4 °C, and the 
membranes were stored at -70 °C until use.  
 
2.3. ATPase assay 
ATPase activity of the isolated NIH 3T3 MDR1 cell membranes was estimated by 
measuring inorganic phosphate liberation (Sarkadi et al., 1992). Membrane suspensions 
containing 5 µg membrane protein were preincubated in 60 µl ATPase assay mix (50 mM 
MOPS, 65 mM KCl, 6.5 mM NaN3, 2.6 mM DTT, 1.28 mM oubain, 0.65mM EGTA, 
adjusted to pH 7.0 with Trisma-base) in the presence or absence of 100 µM Na3VO4 
(vanadate) at 37 °C. The assay mix also contained the studied agent at different 
concentrations and 40 µM verapamil as stimulator agent in the stimulated samples. The 
reaction was started by adding 10 µl ATP/Mg2+ to a final concentration of 3.2 mM. After 30 
minutes incubation at 37 °C, the reaction was stopped by 40 µl 5 % SDS, then the samples 
were incubated with 105 µl color reagent (10 volume of reagent A, 6 volume of reagent B and 
5 volume of reagent C) at room temperature for 30 min. The composition of the reagents was 
the following; reagent A: 1.5 M H2SO4, 1% ammonium molybdate, and 0.014% antimony 
potassium tartrate, reagent B: 20 % acetic acid, reagent C: 1% ascorbic acid), After the 
incubation the absorbance of the samples was determined at 700 nm by Biotek Synergy HT 
plate reader and the amounts of the liberated phosphate (Pi) were calculated. The differences 
between ATPase activities measured in the absence and the presence of vanadate (100 µM) 
are considered as Pgp dependent ATPase activity, since the ATPase activity of ABC 
transporters is inhibited by vanadate and this cell line does not express other drug transporting 
ABC proteins at significant level (our unpublished data and Ambudkar et al., 1998). 
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2.4. Radiotracers 
The glucose analog 2-deoxy-2-[18F]fluoro-D-glucose (18FDG) was synthesized and 
labeled with the positron-decaying isotope 18F according to Hamacher et al. (Hamacher et al., 
1986). The synthesis was performed on a commercially available GE Tracerlab FXFDG 
module. The radiochemical purity of 18FDG was better than 99 %. The specific activity of 
18FDG was 27±6.5 GBq/µmol. 
 
2.5. log P (octanol/water partition coefficient) determination 
The determination of log P value was performed as we described earlier (Márián et al., 
2005). Half milliliter of octanol was added to a centrifuge tube containing 0.5 ml of PBS + 5 
µCi (0.185 MBq) 18FDG. The mixture was shaken intensively for 20 minutes and the tubes 
were centrifuged at 1000 × g for 20 min. The radioactivities of the octanol and water phases 
were measured with a calibrated Canberra Packard gamma counter. The log ratio of the 
18FDG concentrations in the octanol and water phases was calculated. 
 
2.6. In vitro radiotracer uptake and efflux studies of cancer cells measured in cell 
suspension 
The cells were washed and resuspended in PBS containing 1 mM glucose (gl-PBS). 
The samples were preincubated at 37 °C for 10 min at a cell concentration of 1 × 106 ml−1 in 
PBS. 10 μCi (0.37 MBq)/ml 18FDG was then added to each sample. After the addition of the 
radioligand, cells were further incubated at 37 °C for 30 min. After these steps the control 
samples (18FDG accumulation for 30 min) were washed 3 times with ice-cold PBS and 
resuspended in 1 ml of cold PBS, and the radioactivity was measured. 
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For the investigation of 18FDG efflux the samples were first loaded with 18FDG (at 
37 °C for 30 min) and then washed with gl-PBS at room temperature. After centrifugation the 
supernatant was removed and the cells were resuspended in 2 ml 37°C gl-PBS and further 
incubated at 37 °C for 10-30 min. The efflux was terminated by the addition of ice-cold PBS. 
The cells were then washed twice with ice cold PBS and the radioactivity was measured in a 
Canberra Packard gamma-counter for 1 min within the 18F-sensitive energy window. Decay-
corrected radiotracer uptake was expressed as counts min−1 (106 cells)−1 (cpm). The displayed 
data are the means of at least three independent experiments (± SD) carried out using different 
cell passages, and each experiment was performed in triplicate.  
 
2.7. In vitro 18FDG uptake and efflux of cancer cells measured in monolayer, using a 
miniPET camera 
The Pgp+ and Pgp- cell pairs were cultured (0.4-0.5 × 106 cells in 2 ml culture medium) 
in Petri dishes (40 × 11mm) for 24-30 hours. By the end of the culture period the cells were 
grown in monolayer and covered 70-80% of the Petri dishes. Before the 18FDG uptake studies 
the cell cultures were washed with 2 ml DMEM containing 1mM glucose (gl-DMEM). After 
washing, the cells were incubated with 100 µCi (3.7 MBq)/2 ml 18FDG for 30 minutes in gl-
DMEM at 37°C in a 95% humidified air, 5% CO2 atmosphere. Thereafter the samples were 
washed twice at room temperature. Following that 2 ml gl-DMEM was added to each sample 
and the 18FDG uptake was determined by the MiniPET-II scanner (Lajtos et al., 2013). 2 min 
acquisition time was used. After the first PET scans the samples were incubated for other 30 
or 60 minutes at 37°C in a 95% humidified air, 5% CO2 atmosphere. After the incubation time 
the supernatant (medium) was discarded and 2 ml gl-DMEM was added to each sample. The 
retained 18FDG was determined by the MiniPET-II scanner, using the same acquisition time 
(2 min). After the PET scans the cells were trypsinized, resuspended in PBS and the cell 
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numbers were determined. The viability of the cells used in our experiments was always 
higher than 90%, as assessed by the trypan blue exclusion test. All experiments were carried 
out using different cell passages and the means (±SD) of at least three independent 
experiments are given. 
 
 
 
2.8. 18FDG-PET data analysis 
Ellipsoidal 3-dimensional regions of interest (ROI) were manually drawn around the 
edge of the tissue culture dish using BrainCad software (http:/www.minipetct.hu). The 18FDG 
uptake was expressed in Bq/ml. 
 
2.9. Indirect immunofluorescence  
Formaldehyde (1% in PBS) prefixed cells were centrifuged at 500 × g for 5 min and 
washed twice with 1% PBS/BSA. To visualize the Pgp expression, cells (1 × 106 cells/ml) 
were incubated with 10 µg/ml of UIC2 mAb in PBS containing 1% BSA (PBS/BSA) at 37◦C 
for 40 min. The UIC2 mAb was purified from the supernatant of a hybridoma (purchased 
from the American Type Culture Collections, Manassas, VA, USA) using affinity 
chromatography. The anti-Pgp mAb preparations were >97 % pure by SDS/PAGE. After two 
washes with ice-cold PBS, the cells were incubated with rabbit anti-mouse Alexa 488 
secondary antibody (10 µg/ml A488-GaMIgG, Invitrogen, CA) at 4 ◦C for 30 min.  
For the detection of glucose transporters and hexokinase expression, the cells were 
incubated with the primary antibodies: Rabbit polyclonal to glucose transporter GLUT-1, 
GLUT-3 (Abcam, diluted 1:250) and Rabbit anti type II hexokinase polyclonal (Chemicon, 
Millipore, diluted 1:500) antibodies at room temperature for 60 min. After two washes with 
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ice-cold PBS the cells were incubated with goat anti-rabbit Alexa 488 secondary antibody 
(10µg/ml A488-GaRIgG, Invitrogen, CA) at 4 ◦C for 30 min. Negative controls were obtained 
by omitting the primary antibody. 
 
2.10. Rhodamine 123 accumulation experiments 
To demonstrate the function of Pgp in 18FDG accumulation or efflux experiments and 
to study the effect FDG and deoxy-glucose metabolites on the transport activity of Pgp 
rhodamine 123 (R123) accumulation measurements were carried out. The cells were washed 
and re-suspended in PBS containing 5 mM glucose. The samples (1 × 106 cells ml−1 in PBS) 
were pre-incubated at 37 °C for 5 min in the presence or absence (control) of CSA 
(Cyclosporin A, 10 µM), verapamil (50 µM), FDG, DG, DG6PO4 or ClDG (1, 100 and 1000 
µM) and then further incubated at 37 °C for another 20 min in the presence of 0.5 µM R123. 
R123 uptake was terminated by the addition of ice-cold PBS. The means of the fluorescence 
intensity histograms were calculated on the basis of 10 000 individual cells, collected in list 
mode.   
 
2.11. Flow cytometry 
A Becton Dickinson FACScan flow cytometer (Becton-Dickinson, Mountain View, 
CA) was used to determine the fluorescence intensities.  Alexa 488 and R123 were excited by 
the 488 nm line of a solid state laser and the emitted light was detected using a 502 nm 
dichroic mirror and a 530/30 nm band-pass filter. Cytofluorimetric data were analyzed by 
BDIS CELLQUEST (Becton-Dickinson) software. 
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2.12. Data analysis 
The data were expressed as means ± S.D. Tracer accumulation data were compared 
with those measured under control conditions by using Student's t-test (two-tailed) and the 
level of significance was set to p ≤ 0.05. When 18FDG accumulation or expression of glucose 
transporters and hexokinase-II were examined in the Pgp+ and Pgp- cell pairs we applied z-
test comparing the mean of the related Pgp+/Pgp- ratios to 1 as a constant and the significance 
level was set to 0.05 as previously.   
 
3. Results 
 
3.1. Distribution of 18FDG between the octanol and water phase 
We determined the distribution of the 18FDG between the aqueous and octanol phases 
and found that the log P value was -2.018±0.03 (n=9) supporting its hydrophilic character. 
 
3.2. Effect of FDG and its metabolites on the R123 uptake of Pgp expressing cells  
To test whether FDG and its metabolites interact with Pgp as a substrate or inhibitor 
we carried out substrate accumulation experiments using rhodamine 123 (R123), a high 
affinity fluorescent substrate of Pgp. To simulate the in vivo conditions and prevent the 
starvation of the cells the extracellular glucose concentration was held at 5 mM. The R123 
uptake of the Pgp+ and Pgp- cells was measured in the presence or absence of different 
concentrations of FDG or deoxy-glucose derivatives (between 1µM to 1 mM).  As it is shown 
in Table 1., Pgp- cells accumulated R123 at high level, while Pgp+ cells extruded R123 
resulting in much lower R123 fluorescence intensity. Competitive inhibitors of Pgp strongly 
increased the R123 uptake of Pgp+ cells, while did not affect that of the Pgp- cells. FDG and 
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the applied deoxy-glucose derivatives did not have any effect on the R123 uptake of either 
cell lines suggesting that these agents are not substrates or modulators of Pgp.  
 
 3.3. Effect of FDG on the ATPase activity of Pgp 
R123 accumulation assays carried out with intact cells imply that the exact 
intracellular concentration of FDG and its derivatives is determined by glucose transport 
mechanisms and consequently is not equal to the extracellular concentration. Thus, we 
switched to ATPase activity measurements using membrane samples (containing 
predominantly inside-out vesicles or unsealed membranes), where the concentration of FDG 
and its derivatives in the aqueous phase is equal to the applied concentration. Since Pgp is an 
ATP driven active transporter, ATPase activity is required to fuel transport activity. In 
addition, similarly to several other ABC transporters Pgp also has a basal ATPase activity 
which can be observed in the absence of treatments with Pgp substrates (black circles), while 
addition of transport substrates e.g. verapamil stimulates the ATPase activity of the pump in a 
concentration dependent manner (Fig. 1a). The maximal stimulation of the ATPase activity is 
between 2 to 10 fold depending on the substrate. Co-treatment with competitive Pgp 
inhibitors e.g. cyclosporin A decreases the verapamil stimulated ATPase activity in a 
concentration dependent manner (Fig. 1b). Applying the same method we measured the effect 
of different 2-deoxy-glucose derivatives 2-fluoro-deoxy-glucose (FDG, Fig. 1c), 2-chloro-2-
deoxy-glucose (Fig. 1d), 2-deoxy-D-glucose (Fig. 1e) and 2-deoxy-D-glucose-phosphate (Fig. 
1f) on the basal and the substrate stimulated ATPase activity of Pgp. None of these agents had 
any effect on the basal or the 50 µM verapamil stimulated ATPase activity of Pgp, suggesting 
that these agents are not substrates or inhibitors of Pgp.  
 
3.4. Pgp, glucose transporter and hexokinase-II expression 
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Pgp expression was detected by means of indirect immunofluorescence using a 
monoclonal antibody (UIC2) that recognizes an extracellular epitope of the protein. The mean 
fluorescence intensity of the UIC2 labeled cells was normalized to that of the isotype control 
to calculate a signal to background ratio. 
The ratio of the relative mean fluorescence intensities of the Pgp+/ Pgp- ovarian 
carcinoma A2780AD/A2780, the epidermoid adenocarcinoma KB-V-1/KB-3-1 and mouse 
fibroblast cells were 14.7±3.3, 12.0±2.2 and 13±2, respectively (n=3). The above data 
demonstrate that the Pgp+ cells express Pgp at high level. The R123 accumulation studies 
shown in Table 1 demonstrate that the applied Pgp+ cell lines express functional transporter 
molecules. The expression of glucose transporters and hexokinase-II enzyme in Pgp+ and Pgp- 
cell lines were also determined (Fig. 2). The glucose transporter expression was detected by 
means of indirect immunofluorescence using monoclonal antibodies and normalized to that of 
the isotype control. The ratios of the mean fluorescence intensities of the Pgp+/Pgp- were 
calculated. All of the examined protein expressions were slightly higher in the Pgp+ cells, but 
these differences were not significant at p ≤ 0.05. 
 
3.5. 18FDG accumulation and washout kinetics measured in cell suspension and monolayer 
The 18FDG uptake and washout kinetics of the Pgp+ and Pgp- cell line pairs were 
measured both in suspension and in monolayer (Fig. 3). The 18FDG uptakes of all three Pgp+ 
cells were significantly higher (p ≤ 0.01) measured both in suspension and in monolayer than 
that of their Pgp- counterparts after 30 min incubation time, except the 3T3MDR1/3T3 cell 
pairs measured in monolayer (Fig. 3a). The 18FDG accumulation rate in the KB-V-1 and 
A2780AD cell lines was significantly higher (p ≤ 0.01) compare to their Pgp- counterparts 
(KB-3-1, A2780) when measured in suspension than when it was measured in monolayer, 
except the 3T3MDR1/3T3 cell pairs measured in suspension and monolayer (Fig. 3a). 
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Although the washout kinetics of 18FDG in the Pgp+ cell lines were moderately faster, than 
that of their Pgp- pairs measured in suspension (both after 10 and 30 min. incubation time) the 
differences generally were not significant. However, significant differences were found in the 
retained 18FDG fractions measured in suspension after 30 min washout time (see Fig. 3b) 
between the  Pgp+ and Pgp- KB cells (p = 0.04), and in case of the A2780 cell line pair (p = 
0.065).  
Similar tendency was obtained using adherent monolayer cultures but the differences 
between the Pgp+ and Pgp- cell lines were even less (Fig. 3c), and were not statistically 
significant.
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4. Discussion 
Currently 18FDG is the most important PET radiotracer used in routine clinical cancer 
imaging, from diagnosing the malignancy to measuring its response to chemotherapy and/or 
radiation therapy in a wide range of human cancers including gynecologic tumors 
(Vallabhajosula, 2007; Kitajima et al., 2011).  
Several authors reported that the accumulation of 18FDG differs between Pgp 
expressing and non-expressing cancer cells and tumors (Lorke et al., 2001; Márián et al., 
2003; Higashi et al., 2004; Yamada et al., 2005; Krasznai et al., 2006; Seo et al., 2009; 
Krasznai et al., 2010; Smith, 2010). A number of them accounted decreased accumulation of 
18FDG in cancer cells and tumors expressing Pgp at high level (Lorke et al., 2001; Higashi et 
al., 2004; Yamada et al., 2005; Seo et al., 2009; Smith, 2010, Yu et al., 2012). The most 
obvious interpretation of this observation would be that 18FDG is a substrate of Pgp. 
However, there are no exact experiments available in the literature up till now supporting this 
assumption. The aim of this study was to investigate whether the 18FDG and its metabolites 
are substrates or modulators of Pgp.  
Pgp is an ATP-dependent drug efflux pump exhibiting extremely wide substrate 
spectrum. It exports structurally unrelated compounds out of cells at the expense of ATP 
hydrolysis, keeping intracellular levels of chemotherapeutics below a toxic threshold. Pgp is 
referred as a “hydrophobic vacuum cleaner”, because it is believed to extract its substrates 
directly from the inner leaflet of the plasma membrane (Homolya et al., 1993; Shapiro and 
Ling, 1997, 1998). In accordance with it Pgp substrates are hydrophobic substances (Sarkadi 
et al., 1994) with logP values in the range of 2 to 5. For instance the logP value of verapamil 
is 3.78 (Buchwald and Bodor, 1998), and a competitive Pgp inhibitor cyclosporin A has a log 
P value of 2.92 (el Tayar et al., 1993). We found that the logP value of 18FDG is -2.02, which 
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demonstrates its hydrophilic character and does not support its direct interaction with Pgp as a 
substrate or modulator. 
In R123 accumulation assay competitive inhibitors of Pgp (verapamil and CSA) 
increased the dye uptake of the Pgp+ cells, while FDG and its derivatives did not have any 
effect (Table 1). To further test whether FDG is a substrate or modulator of Pgp we carried 
out ATPase activity measurements. Pgp exhibits a high-capacity substrate-dependent ATP 
hydrolytic activity that is a direct reflection of its substrate transport capability (Scarborough, 
1995). Substrates readily stimulate the ATPase activity of Pgp, while competitive inhibitors 
bind tightly to the drug-binding site inhibiting substrate transport as well as ATP hydrolysis.  
We found in our ATPase assay that FDG does not affect the ATPase activity of Pgp 
(Fig. 1) further supporting that it is not a substrate or inhibitor of the transporter. FDG is 
converted to FDG-6-P very rapidly (Kaarstad et al. 2002). FDG-6-P is not commercially 
available, therefore we used the 2-deoxy-glucose-6-phosphate in our experiments, which has 
very close chemical characters to that of the FDG-6-P molecule and found that it does not 
have any influence on the ATPase activity of Pgp. Collectively, these results strongly suggest 
that 18FDG and the derivatives of 2-deoxy-D-glucose are hydrophilic substances and do not 
interact with Pgp as a substrate or inhibitor. Thus, it seems likely that other mechanisms are 
behind the decreased 18FDG accumulation by the Pgp+ cells or tumors experienced in several 
previous studies. 
The increased energy demand of the cancer cells manifests in higher glucose 
metabolisms that can be followed by measuring 18FDG accumulation. 18FDG is a glucose 
analog that is taken up by facilitated diffusion through glucose transporter molecules (GLUT) 
and phosphorylated by hexokinases in the cells similarly to the glucose molecule. Thus the 
expression and activity of the GLUT transporters and hexokinases may affect the glucose 
metabolism of tumor cells and consequently the 18FDG uptake into the tumors (Wahl, 1996; 
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Vallabhajosula, 2007; Smith, 2010; Breier et al., 2013). In line with the above assumptions 
numerous studies compared the level of GLUT transporters, the hexokinase activity and the 
18FDG accumulation of different tumor cells. Several authors reported strong positive 
correlation between the GLUT transporter expression, the 18FDG uptake and the malignancy 
of tumors, while others found only weak correlations (Lorke et al., 2001; Zhao et al., 2005; 
Smith et al., 2007; Vallabhajosula, 2007; Ong et al., 2008; Paudyal et al., 2008; Seo et al., 
2009; Smith, 2010;). Zaho et al. (2005) and Yu et al. (2012) demonstrated that the intra-
tumoral 18FDG distribution correlates well with the expression levels of GLUT-1, GLUT-3, 
and Hexokinase-II.  In line with the above Southworth et al. (2003) suggested tissue specific 
differences in the phosphorylation rate of 18FDG to 18FDG -6-phosphate. The elevated 
expression levels of GLUT-1, GLUT-3, and HK-II, induced by hypoxia (HIF-1α), may be 
also be contributing factors to the higher 18FDG accumulation in the tumor region. Hypoxic 
conditions linked to an increase in HIF-1α expression may affect the expression and transport 
function of Pgp as well (Breier et al., 2013). In contrary, Seo et al. (2009) measuring the 
18FDG accumulation in hepatic cells and tumors found that the GLUT-2 and hexokinase II 
expression and the glucose-6-phosphatase activity did not correlate with tumor differentiation 
and 18FDG SUV value.  
In our present work, we also examined the correlation between the 18FDG uptake and 
the expression level of GLUT transporter molecules, and hexokinase II molecules in three 
cancer cell line pairs (Pgp+ and Pgp-) with different tissue origin. However, we did not find 
strong correlation between the 18FDG accumulation and the expression level of GLUT 
transporters and hexokinase molecules (compare Fig. 2 and Fig. 3a). 
Interestingly, we measured significantly higher 18FDG accumulation in the Pgp+ cell 
lines compared to their Pgp- counterparts (Fig. 3a), in agreement with our previous results 
(Márián et al., 2003, 2005; Krasznai et al., 2006). Pgp is a transport ATPase with high basal 
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ATPase activity that is further increased in the presence of substrates (see Fig. 1). Thus, 
expression of Pgp at high level may increase the ATP demand of cells explaining our 
observations. 
Yu et al. also (2012) measured an increased in vitro uptake of 18FDG into the Pgp+ 
Bcap37/MDR1 human breast carcinoma cell line compared to its Pgp- counterpart (Bcap37) 
upon short (10 min) incubation. Similarly, in their in vivo 18FDG uptake experiments they also 
measured higher 18FDG accumulation in the Bcap37/MDR1 tumors compared to the Bcap37 
tumors. It is fully consistent to our result reported in this study. Interestingly, this trend 
reversed upon long (60 to 120 min) exposure in their experiments, where higher 18FDG 
uptake was measured in the Bcap37 cell line compared to the Bcap37/MDR1 cell line, 
however there is no exact explanation for this observation.  In addition, induction of other yet 
unknown mechanisms could also behind this virtual discrepancy. 
We obtained higher values of 18FDG accumulation measured in cell suspension than in 
monolayer, supporting, that the experimental conditions may cause remarkable differences in 
the 18FDG accumulation in case of the same cell lines (Márián et al., 2000).   
In efflux measurements we observed slightly faster 18FDG efflux from the Pgp+ KB-
V-1 and A2780AD cells compared to their Pgp- counterparts (Fig. 3b and c).  Since the 
elevated efflux rate was measured in those cells that accumulated the highest amount of 
18FDG (Fig. 3a), it is probably explained by an increased production of the dephosphorylated 
18FDG by the glucose-6-phosphatase enzyme and its concomitant transport by glucose 
transporter molecules.   
 Taken together our results 18FDG is not a substrate or modulator of Pgp, thus its 
uptake into either Pgp+ or Pgp- cells seems to be a true reflection of the glucose metabolism of 
cells and tissues.  Consequently, 18FDG uptake is determined by factors affecting the energy 
demand and glucose metabolism of cells e.g. cell viability, tumor perfusion, hypoxia, 
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inflammation, chemotherapy, radiation therapy, necrosis and expression level of active 
transporters including Pgp.  
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Figure legends 
 
Fig. 1. Effects of cyclosporin A (b), 2-fluoro-deoxy-glucose (FDG, c), 2-chloro-2-deoxy-
glucose (d), 2-deoxy-D-glucose (e) and 2-deoxy-D-glucose-phosphate (f) on the basal (filled 
symbol) and on the 50 µM verapamil stimulated (empty symbol) ATPase activity of Pgp in 
membrane samples prepared from NIH 3T3 MDR1 cells. Panel a shows the concentration 
dependent stimulation of the ATPase activity by verapamil. The data points are means of 
three parallel samples (± SD). The concentrations of the tested agents were varied as shown 
on the abscissa. The data points are means of three parallel samples (± SD). Each experiment 
was repeated twice with similar results.  
 
Fig. 2. Flow cytometric analyses of glucose transporters (GLUT-1, GLUT-3) and HK-II 
expression in tumor cells. Figure shows the ratios of relative mean fluorescence intensities of 
Pgp+ and Pgp- human epidermoid and ovarian carcinoma cell lines. Data are presented as 
mean ± SD of the results of three independent experiments. 
 
Fig. 3. 18FDG accumulation and washout kinetic of Pgp+ and Pgp- cancer cell lines measured 
in suspension and monolayer. a 18FDG uptake ratio of the Pgp+ and Pgp- cell line pairs 
measured in suspension (open square) and monolayer (filled square). Significant differences 
at p≤0.01 are indicated with symbol *. The data points are means ± SD of 4 independent 
experiments measured in triplicates. b One million cells were incubated in PBS containing 5 
µCi (0.185 MBq)/ml 18FDG for 30 min than the incubation solution was changed for 18FDG 
free solution, and farther incubated for 10 or 30 min. respectively. The remained 18FDG 
content of the cells was normalized to the 30 min. 18FDG accumulation value of the cells 
(control=100%). The data points are means ± SD of 4 independent experiments measured in 
  
 28
triplicates. c Cell monolayers were incubated with 50 µCi (1.85 MBq)/ml 18FDG and the 
18FDG accumulation and efflux was measured with miniPET camera as described in the 
Material and methods. The remained 18FDG content (after 30 and 60 min. incubation with 
18FDG free incubation solution) of the cells was normalized to the 30 min 18FDG 
accumulation value of the cells (control=100%). The data points are means ± SD of 4 
independent experiments. 
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Table 1. Effect of FDG and its metabolites on the R123 uptake of Pgp expressing cells 
(mean±SD of 4 independent experiments) 
 
Treatment 
(µM) 
KB-V-1 KB-3-1 A2780AD A2780 3T3 MDR1 3T3 
 R-123 uptake (fluorescence intensity arb. unit) 
untreated 507±97 25059±2512 295±41 10660±1480 2378±404 33535±1496
2-fluoro-deoxy-glucose 
1 509±89 24634±2452 276±27 9984±1167 2379±184 32643±1612
100 498±79 24277±2122 293±36 10159±1008 2417±233 33039±3294
1000 528±78 25990±1801 317±43 10176±1148 2289±356 32691±2036
2-deoxy-D-glucose 
1 542±49 27444±1477 392±28 9739±992 2360±287 28961±3062
100 587±44 24211±1841 334±42 9546±804 2309±195 31828±2667
1000 510±49 23895±1791 405±46 9996±978 2249±263 30740±3568
2-deoxy-D-glucose-phosphate 
1 478±69 24747±2009 319±37 10016±1194 2404±262 34337±1984
100 490±60 24765±2247 311±32 10217±1865 2428±211 32938±2939
1000 510±65 23036±2795 319±46 9940±1461 2355±225 30873±2214
2-chloro-2-deoxy-glucose 
1 486±58 24544±2864 296±39 10239±1234 2378±306 32896±2249
100 500±62 23986±2312 280±32 9978±1062 2275±283 31702±1950
1000 497±48 24391±2989 314±34 9928±951 2297±193 33596±2214
Cyclosoprin A 
10 12806±1165 24316±1058 6453±637 9734±1177 23211±2005 32602±3581
Verapamil 
50 4442±436 20200±355 1749±81 9184±90 8253±1119 29788±104 
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